AR095610A1 - Proteínas de unión de antígeno humano que se unen a la proproteína convertase subtilisin kexin type 9 - Google Patents
Proteínas de unión de antígeno humano que se unen a la proproteína convertase subtilisin kexin type 9Info
- Publication number
- AR095610A1 AR095610A1 ARP140101235A ARP140101235A AR095610A1 AR 095610 A1 AR095610 A1 AR 095610A1 AR P140101235 A ARP140101235 A AR P140101235A AR P140101235 A ARP140101235 A AR P140101235A AR 095610 A1 AR095610 A1 AR 095610A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding proteins
- antigen binding
- polypeptides
- derivatives
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Composiciones y métodos relacionados con o derivados de proteínas de unión del antígeno capaces de inhibir PCSK9 uniéndose a LDLR y tener mayor sensibilidad de pH, mayor afinidad o aumento en la vida media in vivos. En realizaciones, las proteínas de unión de antígeno unen PCSK9 específicamente y han aumentado la sensibilidad pH, mayor afinidad o aumento en vivos de la vida media. En algunas realizaciones la proteína que se une al antígeno completamente humana, humanizada, o anticuerpos quiméricos, fragmentos de unión y derivados de tales anticuerpos y polipéptidos que específicamente unen PCSK9. Otras realizaciones proporcionan ácidos nucleicos que codifican tales proteínas de unión de antígeno y fragmentos y sus derivados y polipéptidos, células que comprende tales polinucleótidos, métodos de hacer tales proteínas de unión de antígeno y fragmentos y sus derivados y polipéptidos, y métodos del uso de tales proteínas de unión de antígeno, fragmentos y sus derivados y polipéptidos, incluidos los métodos de tratamiento o diagnóstico de sujetos que padecen hipercolesterolemia y trastornos relacionados o condiciones. Composición farmacéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799355P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095610A1 true AR095610A1 (es) | 2015-10-28 |
Family
ID=50686167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101235A AR095610A1 (es) | 2013-03-15 | 2014-03-17 | Proteínas de unión de antígeno humano que se unen a la proproteína convertase subtilisin kexin type 9 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160032014A1 (es) |
| EP (1) | EP2968985A2 (es) |
| AR (1) | AR095610A1 (es) |
| TW (1) | TW201525004A (es) |
| UY (1) | UY35486A (es) |
| WO (1) | WO2014144080A2 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2275443T3 (pl) | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CN104080909A (zh) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
| EP2940135B9 (en) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
| EP3383430A4 (en) * | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
| MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
| US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| US20210148909A1 (en) * | 2017-05-31 | 2021-05-20 | North Carolina Central University | Optimization of an active pcsk9 assay |
| JP2021502967A (ja) | 2017-11-14 | 2021-02-04 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体および使用方法 |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN110892990B (zh) * | 2019-10-11 | 2023-03-31 | 内蒙古伊利实业集团股份有限公司 | 益生菌益生元食用组合物及其应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN115469106B (zh) * | 2022-09-16 | 2024-05-17 | 天津科技大学 | 一种冻干细胞膜碎片复溶液、复溶方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011348232A1 (en) * | 2010-12-22 | 2013-07-18 | Genentech, Inc. | Anti-PCSK9 antibodies and methods of use |
| MX2013009258A (es) * | 2011-02-11 | 2013-10-17 | Novartis Ag | Antagonistas de pcsk9. |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2014
- 2014-03-14 US US14/777,401 patent/US20160032014A1/en not_active Abandoned
- 2014-03-14 EP EP14722880.3A patent/EP2968985A2/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/028339 patent/WO2014144080A2/en active Application Filing
- 2014-03-17 UY UY0001035486A patent/UY35486A/es not_active Application Discontinuation
- 2014-03-17 TW TW103109996A patent/TW201525004A/zh unknown
- 2014-03-17 AR ARP140101235A patent/AR095610A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY35486A (es) | 2014-09-30 |
| TW201525004A (zh) | 2015-07-01 |
| WO2014144080A3 (en) | 2014-12-18 |
| WO2014144080A2 (en) | 2014-09-18 |
| EP2968985A2 (en) | 2016-01-20 |
| US20160032014A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095610A1 (es) | Proteínas de unión de antígeno humano que se unen a la proproteína convertase subtilisin kexin type 9 | |
| WO2014150983A3 (en) | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9) | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| BR122018012430B8 (pt) | anticorpo monoclonal que se liga a pcsk9 humana, e, composição farmacêutica | |
| EA201391157A1 (ru) | Антагонисты pcsk9 | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
| EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
| EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| EA201492149A8 (ru) | St2-антигенсвязывающие белки | |
| EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
| TR201809571T4 (tr) | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. | |
| UY34975A (es) | ANTICUERPOS ANTI-PCSK9 CON CARACTERÍSTICAS DE UNIÓN DEPENDIENTES DEL pH | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
| AR092005A1 (es) | Anticuerpos anti-pcsk9 y uso de los mismos | |
| CL2011000010A1 (es) | Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende. | |
| NI201700012A (es) | Inhibidores de la proteina quinasa c y métodos de su uso | |
| EA201691027A1 (ru) | Модуляторы aplnr и их применение | |
| EA201391753A1 (ru) | Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA201691176A1 (ru) | АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ | |
| EA201592267A1 (ru) | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |